Therapies and Preventive Strategies for Recurrent Clostridium Difficile Infections

home / peer-exchange / therapies-and-preventive-strategies-for-recurrent-clostridium-difficile-infections

A panel of experts share payer and clinical considerations for recurrent clostridium difficile infection, including recommend treatment pathways, unmet needs, and emerging therapies.

Episodes

Experts on clostridium difficile infection

November 18th 2021EP. 1: Defining Traditional Risk Factors for Developing C. Diff Infection

Neil Minkoff, MD;Dale N. Gerding, MD ;Jessica Allegretti, MD, MPH ;Kevin U. Stephens, Sr, JD, MD ;Karina Abdallah, PharmD

Opening their discussion, panelists elucidate patient factors that may impact risk of developing clostridium difficile infection.

November 18th 2021EP. 2: Recurrent CDI: Risk Factors and Outcomes

Neil Minkoff, MD;Dale N. Gerding, MD ;Jessica Allegretti, MD, MPH ;Kevin U. Stephens, Sr, JD, MD ;Karina Abdallah, PharmD

Experts focus on recurrent clostridium difficile infection to define risk factors and discuss impact on patient outcomes.

November 24th 2021EP. 3: Impact of Recurrent CDI on Patients and the Healthcare System

Neil D. Minkoff, MD;Dale N. Gerding, MD ;Jessica Allegretti, MD, MPH ;Kevin U. Stephens, Sr, JD, MD ;Karina Abdallah, PharmD

A broad view on the impact of recurrent clostridium difficile infection on patients and the healthcare system at large.

November 24th 2021EP. 4: Identifying Treatment Goals for Recurrent CDI

Neil D. Minkoff, MD;Dale N. Gerding, MD ;Jessica Allegretti, MD, MPH ;Kevin U. Stephens, Sr, JD, MD ;Karina Abdallah, PharmD

A panel of experts review treatment goals and assessing response in patients with recurrent clostridium difficile infection.

December 2nd 2021EP. 5: Treatment Guidelines and Recommendations for C. Diff Infection

Neil D. Minkoff, MD;Dale N. Gerding, MD ;Jessica Allegretti, MD, MPH ;Kevin U. Stephens, Sr, JD, MD ;Karina Abdallah, PharmD

Shared insight on the differences between ACG and IDSA/SHEA treatment guidelines for patients with clostridium difficile infection.

December 2nd 2021EP. 6: Payer Perspectives on Coverage Criteria for Clostridium Difficile Treatments

Neil Minkoff, MD;Dale N. Gerding, MD ;Jessica Allegretti, MD, MPH ;Kevin U. Stephens, Sr, JD, MD ;Karina Abdallah, PharmD

Payer participants break down how coverage criteria are determined for treatments for clostridium difficile infection.

December 9th 2021EP. 7: Practical Considerations for Fidaxomicin Use in Recurrent CDI

Neil Minkoff, MD;Dale N. Gerding, MD ;Jessica Allegretti, MD, MPH ;Kevin U. Stephens, Sr, JD, MD ;Karina Abdallah, PharmD

Focused discussion on the use of fidaxomicin for clostridium difficile infection, and possible barriers to the selection of this agent.

December 9th 2021EP. 8: Defining Value in Recurrent CDI

Neil Minkoff, MD;Dale N. Gerding, MD ;Jessica Allegretti, MD, MPH ;Kevin U. Stephens, Sr, JD, MD ;Karina Abdallah, PharmD

An overview on how the cost of therapy for recurrent clostridium difficile infection may impact treatment planning.

December 16th 2021EP. 9: Bezlotoxumab Use in Patients at High Risk for CDI Recurrence

A brief review of the role of bezlotoxumab therapy for patients at high risk for clostridium difficile infection recurrence.

December 16th 2021EP. 10: Payer Perspectives on Risk Stratification for CDI Recurrence

Neil Minkoff, MD;Dale N. Gerding, MD ;Jessica Allegretti, MD, MPH ;Kevin U. Stephens, Sr, JD, MD ;Karina Abdallah, PharmD

Payer participants consider how they proactively risk stratify patients for clostridium difficile infection recurrence.

December 23rd 2021EP. 11: Challenges in the Management of C. Diff Infection

Neil Minkoff, MD;Dale N. Gerding, MD ;Kevin U. Stephens, Sr, JD, MD ;Jessica Allegretti, MD, MPH ;Karina Abdallah, PharmD

Panelists take a step back to consider the broader challenges in managing patients with clostridium difficile infection.

December 23rd 2021EP. 12: An Overview of Fecal Microbiota Transplant Use in C. Diff Infection

Neil Minkoff, MD;Jessica Allegretti, MD, MPH ;Dale N. Gerding, MD ;Kevin U. Stephens, Sr, JD, MD ;Karina Abdallah, PharmD

Experts focus on the current state of fecal microbiota transplant as a treatment option for clostridium difficile infection.

January 4th 2022EP. 13: Barriers to Use of Fecal Microbiota Transplant in C. Diff Infection

Neil Minkoff, MD;Dale N. Gerding, MD ;Jessica Allegretti, MD, MPH ;Kevin U. Stephens, Sr, JD, MD ;Karina Abdallah, PharmD

A focused discussion on the barriers to fecal microbiota transplant for patients with clostridium difficile infection.

January 4th 2022EP. 14: C. Diff Infection: Patient Access to Fecal Microbiota Transplant

Neil Minkoff, MD;Dale N. Gerding, MD ;Jessica Allegretti, MD, MPH ;Kevin U. Stephens, Sr, JD, MD ;Karina Abdallah, PharmD

Shared insight on the process to gain access to fecal microbiota transplant for patients with clostridium difficile infection.

January 11th 2022EP. 15: Evolving Medical Policies and Unmet Needs in C. Diff Infection Management

Neil Minkoff, MD;Dale N. Gerding, MD ;Jessica Allegretti, MD, MPH ;Kevin U. Stephens, Sr, JD, MD ;Karina Abdallah, PharmD

Panelists review unmet needs in clostridium difficile infection management and consider how medical policies are evolving to address them.

January 11th 2022EP. 16: Looking Toward the Future: Management of C. Diff Infection

Neil Minkoff, MD;Dale N. Gerding, MD ;Jessica Allegretti, MD, MPH ;Kevin U. Stephens, Sr, JD, MD ;Karina Abdallah, PharmD

Closing out their discussion on recurrent clostridium difficile infection management, experts share closing thoughts and hopes for the future.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions